Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Heparin Sodium
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 29, 2023
Lead Product(s) : Heparin Sodium
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Heparin Sodium
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 29, 2023
Lead Product(s) : Heparin Sodium
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Filgrastim
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 29, 2023
Lead Product(s) : Filgrastim
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ERYTHROPOIETIN
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Asses the Impact of Early Starting Erythropoetin in the Reduction of Transfusions Blood in Childrens
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
January 30, 2023
Lead Product(s) : ERYTHROPOIETIN
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Epoetin Alpha
Therapeutic Area : Hematology
Study Phase : Approved FDF
Recipient : JSR Life Sciences
Deal Size : Undisclosed
Deal Type : Partnership
Similis Bio Partners With Blau Farmaceutica to Co-Develop Four Biosimilar Programs
Details : The agreement, Blau’s most recent move into the biosimilars market, is a multi-product and multi-year deal to develop products and licenses IP for four biosimilar assets targeting indications in oncology, inflammation, and blood disorders.
Product Name : rHuEPO
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
October 25, 2022
Lead Product(s) : Epoetin Alpha
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Recipient : JSR Life Sciences
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : ERYTHROPOIETIN
Therapeutic Area : Nephrology
Study Phase : Phase I
Recipient : Azidus Brazil
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
June 28, 2018
Lead Product(s) : ERYTHROPOIETIN
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Recipient : Azidus Brazil
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ERYTHROPOIETIN
Therapeutic Area : Nephrology
Study Phase : Phase III
Recipient : Azidus Brazil
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
September 28, 2012
Lead Product(s) : ERYTHROPOIETIN
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Recipient : Azidus Brazil
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Heparin Sodium
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Azidus Brazil
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 25, 2012
Lead Product(s) : Heparin Sodium
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Azidus Brazil
Deal Size : Inapplicable
Deal Type : Inapplicable